Back to Browse Journals » OncoTargets and Therapy » Volume 5

Current and emerging treatment options for nasopharyngeal carcinoma

Authors Spratt DE, Lee N

Published Date October 2012 Volume 2012:5 Pages 297—308


Received 24 May 2012, Accepted 22 June 2012, Published 23 October 2012

Daniel E Spratt, Nancy Lee

Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Abstract: In this article, we focus on the current and emerging treatments in nasopharyngeal cancer (NPC). A detailed evolution of the current standard of care, and new techniques and treatment options will be reviewed. Intergroup 0099 established the role for chemoradiotherapy (chemo-RT) in the treatment of nasopharyngeal carcinoma. Multiple randomized Phase III trials have shown the benefit of chemo-RT; however, none of these studies utilized modern radiotherapy (RT) techniques of intensity-modulated radiation therapy (IMRT). IMRT has the ability to deliver high doses of radiation to the target structures while sparing adjacent bystander healthy tissues, and has now become the preferred RT treatment modality. Chemotherapy also has had a shifting paradigm of induction and/or adjuvant chemotherapy combined with RT alone, to the investigation with concurrent chemo-RT. New treatment options including targeted monoclonal antibodies and small molecule tyrosine kinase inhibitors are being studied in NPC. These new biologic therapies have promising in vitro activity for NPC, and emerging clinical studies are beginning to define their role. RT continues to expand its capabilities, and since IMRT and particle therapy, specifically intensity-modulated proton therapy (IMPT), has reports of impressive dosimetric efficacy in-silica. Adaptive RT is attempting to reduce toxicity while maintaining treatment efficacy, and the clinical results are still in their youth. Lastly, Epstein–Barr virus (EBV) DNA has recently been studied for prediction of tumor response and its use as a biomarker is increasingly promising to aid in early detection as well as supplementing the current staging system. RT with or without chemotherapy remains the standard of care for nasopharyngeal carcinoma. Advances in RT technique, timing of chemotherapy, biologically targeted agents, particle therapy, adaptive RT, and the incorporation of EBV DNA as a biomarker may aid in the current and future treatment of nasopharyngeal cancer.

Keywords: nasopharyngeal cancer, radiation, chemotherapy, cancer

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Managing myelodysplastic syndromes in very old patients: a teaching case report

Niscola P, Palombi M, Trawinska MM, Tendas A, Giovannini M, Scaramucci L, Perrotti A, de Fabritiis P

Clinical Interventions in Aging 2013, 8:391-394

Published Date: 11 April 2013

Emerging treatment options for nasopharyngeal carcinoma

Zhang L, Chen QY, Liu H, Tang LQ, Mai HQ

Drug Design, Development and Therapy 2013, 7:37-52

Published Date: 1 February 2013

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma

Fostier K, De Becker A, Schots R

OncoTargets and Therapy 2012, 5:237-244

Published Date: 28 September 2012

Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival

Zarogoulidis P, Mavroudi M, Porpodis K, Domvri K, Sakkas A, Machairiotis N, Stylianaki A, Tsiotsios A, Courcoutsakis N, Zarogoulidis K

OncoTargets and Therapy 2012, 5:231-236

Published Date: 27 September 2012

Denosumab: a new option in the treatment of bone metastases from urological cancers

Yuasa T, Yamamoto S, Urakami S, Fukui I, Yonese J

OncoTargets and Therapy 2012, 5:221-229

Published Date: 21 September 2012

Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial

Yamamoto D, Iwase S, Tsubota Y, Sueoka N, Yamamoto C, Kitamura K, Odagiri H, Nagumo Y

OncoTargets and Therapy 2012, 5:185-189

Published Date: 17 September 2012

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

C-fiber-related EEG-oscillations induced by laser radiant heat stimulation of capsaicin-treated skin

Claudia Domnick, Michael Hauck, Kenneth L Casey, Andreas K Engel, et al.

Journal of Pain Research 2009, 2:49-58

Published Date: 17 March 2009